Background Prostate-specific antigen (PSA) remains as the most used biomarker in the
detection of early prostate cancer (PCa). Clinical practice guidelines (CPGs) are produced to …

Background Several systemic therapeutic options exist for metastatic castrate-sensitive
prostate cancer (mCSPC). Circulating tumor DNA (ctDNA) can molecularly profile metastatic …

Background Prognostic stratification is the cornerstone of management in nonmetastatic
prostate cancer (PCa). However, existing prognostic models are inadequate—often using …

Androgen deprivation therapy as single modality therapy was the standard management for
oligometastatic prostate cancer (PCa). Current paradigm shifts toward a multimodality …

We assessed the effect of screening in the European Randomized study of Screening for
Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991 …

Although prostate cancer is one of the most common cancers in the male population, its
basic biological function at a cellular level remains to be fully understood. This lack of in …

Background Screening for prostate cancer (PCa) has dramatically declined in the United
States (US) since the United States Preventive Services Task Force recommended against …

Therapy resistance is a significant challenge for prostate cancer treatment in clinic. Although
targeted therapies such as androgen deprivation and androgen receptor (AR) inhibition are …

Increased PSA-based screening for prostate cancer has resulted in a growing number of
diagnosed cases. However, around half of these are 'indolent', neither metastasizing nor …

Purpose: To investigate the implications of the introduction of two hormonal therapies,
abiraterone acetate+ prednisone (AA+ P) and enzalutamide (ENZA), for the treatment of …